Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ASCO relevance

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 29, 2023 10:29pm

90 Views

Post# 35421302

RE:RE:RE:RE:ASCO relevance

Patents are inconsequential now that the FDA will grant 13 years of exclusivity on the approval of novel biologics like ONCY's pelareorep.How many times do I need to keep posting this for you to understand?

<< Previous

Bullboard Posts

Next >>

Canadian rare earths stock up as drilling starts at uranium property